Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers

British Journal of Clinical Pharmacology

Volumn , Issue , 2016, Pages 706-716

  Jacobs, Bart A W ^a   Deenen, Maarten J ^a   Pluim, Dick ^a   van Hasselt, J G Coen ^a   Krähenbühl, Martin D ^a   van Geel, Robin M J M ^a   de Vries, Niels ^a   Rosing, Hilde ^a   Meulendijks, Didier ^a   Burylo, Artur M ^a   Cats, Annemieke ^a   Beijnen, Jos H ^a,b   Huitema, Alwin D R ^a   Schellens, Jan H M ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

5 fluorouracil; capecitabine; circadian rhythm; dihydropyrimidine dehydrogenase; thymidylate synthase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DIHYDROURACIL; THYMIDYLATE SYNTHASE; URACIL;

ADULT; ARTICLE; BLOOD LEVEL; CIRCADIAN RHYTHM; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; MALE; MODEL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84982975903     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13007     Document Type: Article

References (48)

1. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203–6.
2. Judson IR, Beale PJ, Trigo JM, Aherne W, Crompton T, Jones D, et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest New Drugs 1999; 17: 49–56.
3. Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics 2011; 21: 237–42.
4. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330–8.
5. Midgley R, Kerr DJ. Capecitabine: have we got the dose right? Nat Clin Pract Oncol 2009; 6: 17–24.
6. Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32: 1031–9.
7. Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, Harper P, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer 2013; 108: 2505–15.
8. Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17: 3455–68.
9. Meulendijks D, Jacobs BAW, Aliev A, Pluim D, van Werkhoven E, Deenen MJ, et al. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele. Int J Cancer 2016; 138: 245–53.
10. Fleming RA, Milano G, Thyss A, Etienne MC, Renée N, Schneider M, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 1992; 52: 2899–902.
11. Van Kuilenburg ABP, Meinsma R, Zoetekouw L, Van Gennip AH. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14 + 1G > A mutation. Int J Cancer 2002; 101: 253–8.
12. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999; 79: 627–30.
13. Van Kuilenburg ABP, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705–12.
14. Sistonen J, Büchel B, Froehlich TK, Kummer D, Fontana S, Joerger M, et al. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics 2014; 15: 1653–66.
15. Zhou ZW, Wang GQ, Wan de S, Lu ZH, Chen YB, Li S, et al. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy 2007; 53: 127–31.
16. Gamelin M, Boisdron-Celle M, Guérin-Meyer V, Delva R, Lortholary A, Genevieve F, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999; 17: 1105–10.
17. Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 2007; 249: 271–82.
18. Thomas F, Hennebelle I, Delmas C, Lochon I, Dhelens C, Garnier Tixidre C, et al. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. Clin Pharmacol Ther 2016; 99: 235–42.
19. Launay M, Dahan L, Duval M, Rodallec A, Milano G, Duluc M, et al. Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer. Br J Clin Pharmacol 2016; 81: 124–30.
20. Jiang H, Lu J, Ji J. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Br J Pharmacol 2004; 141: 616–23.
21. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990; 50: 197–201.
22. Petit E, Milano G, Levi F, Thyss A, Bailleul F, Schneider M. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 1988; 48: 1676–9.
23. Van Kuilenburg AB, Poorter RL, Peters GJ, Van Gennip AH, Van Lenthe H, Stroomer AE, et al. No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil. Adv Exp Med Biol 1998; 431: 811–6.
24. Bjarnason GA, Jordan RC, Wood PA, Li Q, Lincoln DW, Sothern RB, et al. Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol 2001; 158: 1793–801.
25. Lincoln DW, Hrushesky WJM, Wood PA. Circadian organization of thymidylate synthase activity in normal tissues: a possible basis for 5-fluorouracil chronotherapeutic advantage. Int J Cancer 2000; 88: 479–85.
26. Wood PA, Du-Quiton J, You S, Hrushesky WJM. Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther 2006; 5: 2023–33.
27. Lévi F, Zidani R, Misset J. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681–6.
28. Pluim D, Jacobs BAW, Deenen MJ, Ruijter AEM, van Geel RMJM, Burylo AM, et al. Improved pharmacodynamic assay for dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Bioanalysis 2015; 7: 519–29.
29. Pluim D, Schilders KAA, Jacobs BAW, Vaartjes D, Beijnen JH, Schellens JHM. Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells. Anal Bioanal Chem 2013; 405: 2495–503.
30. Pluim D, Jacobs BAW, Krähenbühl MD, Ruijter AEM, Beijnen JH, Schellens JHM. Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination. Anal Bioanal Chem 2013; 405: 2391–5.
31. Jacobs BAW, Rosing H, de Vries N, Meulendijks D, Henricks LM, Schellens JHM, et al. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. J Pharm Biomed Anal 2016; 126: 75–82.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method. Methods 2001; 25: 402–8.
33. Beal S, Sheiner L. NONMEM user guides. Ellicott City, MDd, USA: Icon Development Solutions, 1989.
34. Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol 2013; 2: e50.
35. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2008.
36. Diedenhofen B, Musch J. Cocor: a comprehensive solution for the statistical comparison of correlations. PLoS One 2015; 10:.e0121945
37. Gusella M, Bolzonella C, Crepaldi G, Ferrazzi E, Padrini R. A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele. Pharmacogenomics J 2006; 6: 421–4.
38. Zeng Z-L, Sun J, Guo L, Li S, Wu M, Qiu F, et al. Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients. Chronobiol Int 2005; 22: 741–54.
39. Innominato PF, Lévi FA, Bjarnason GA. Chronotherapy and the molecular clock: clinical implications in oncology. Adv Drug Deliv Rev 2010; 62: 979–1001.
40. Boivin DB, James FO, Wu A, Cho-Park PF, Xiong H, Sun ZS. Circadian clock genes oscillate in human peripheral blood mononuclear cells. Blood 2003; 102: 4143–5.
41. Ebisawa T, Numazawa K, Shimada H, Izutsu H, Sasaki T, Kato N, et al. Self-sustained circadian rhythm in cultured human mononuclear cells isolated from peripheral blood. Neurosci Res 2010; 66: 223–7.
42. Krugluger W, Brandstaetter A, Kállay E, Schueller J, Krexner E, Kriwanek S, et al. Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. Cancer Res 2007; 67: 7917–22.
43. Naguib FN, Soong SJ, el Kouni MH. Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver. Possible relevance to chemotherapy with 5-fluoropyrimidines. Biochem Pharmacol 1993; 45: 667–73.
44. Smaaland R, Laerum OD, Lote K, Sletvold O, Sothern RB, Bjerknes R. DNA synthesis in human bone marrow is circadian stage dependent. Blood 1991; 77: 2603–11.
45. Kristensen MH, Weidinger M, Bzorek M, Pedersen PL, Mejer J. Correlation between thymidylate synthase gene variants, RNA and protein levels in primary colorectal adenocarcinomas. J Int Med Res 2010; 38: 484–97.
46. Monica V, Familiari U, Chiusa L, Rossi G, Novero D, Busso S, et al. Messenger RNA and protein expression of thymidylate synthase and DNA repair genes in thymic tumors. Lung Cancer 2013; 79: 228–35.
47. Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63: 2898–904.
48. Uetake H, Ichikawa W, Takechi T, Fukushima M, Nihei Z, Sugihara K. Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin Cancer Res 1999; 5: 2836–9.